Trials / Completed
CompletedNCT04216888
Biomarkers of Response to Ketamine in Depression: MRI and Blood Assays Before and After Open Label Intranasal Ketamine
Biomarkers of Response to Ketamine in Depression
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Dan Iosifescu · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This pilot study aims to identify predictors of response to intranasal ketamine treatment in patients with treatment-resistant depression. Participants will give a sample of blood and undergo magnetic resonance imaging before and after a single intranasal ketamine treatment. Participants will subsequently receive a second intranasal ketamine treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ketamine Hydrochloride | Intranasal administration of 40mg ketamine hydrochloride using an intranasal mucosal atomization device |
Timeline
- Start date
- 2019-06-26
- Primary completion
- 2020-12-28
- Completion
- 2020-12-28
- First posted
- 2020-01-03
- Last updated
- 2021-01-22
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04216888. Inclusion in this directory is not an endorsement.